Add an SSRI (sertraline or paroxetine) to her buspirone regimen
For a 28-year-old female with PTSD already on buspirone, the best medication to add for anxiety is an SSRI—specifically sertraline or paroxetine—as these are the only FDA-approved medications for PTSD and have the strongest evidence for efficacy in this population. 1, 2, 3
Why SSRIs Are the Clear Choice
The 2024 VA/DoD guideline for PTSD management provides a strong recommendation (the highest level) for using specific SSRIs in PTSD 1. Among all pharmacological options:
- Paroxetine and sertraline are FDA-approved specifically for PTSD 4, 3
- SSRIs demonstrate a 58% response rate versus 35% for placebo, with moderate-certainty evidence 3
- A 2023 network meta-analysis confirmed paroxetine (SMD = -0.48), sertraline (SMD = -0.23), and venlafaxine (SMD = -0.29) as first-line agents 2
Why Not Just Continue Buspirone Alone?
Buspirone has minimal evidence for PTSD treatment. While FDA-approved for generalized anxiety disorder 5, only one small open trial from 1994 (8 patients) suggested potential benefit in PTSD 6. The drug label makes no mention of PTSD as an indication 5. The 2024 VA/DoD guideline does not recommend buspirone for PTSD 1.
Practical Implementation
Start with sertraline or paroxetine:
- Begin at low doses (sertraline 25 mg or paroxetine 10 mg daily)
- Titrate gradually over 1-2 weeks to therapeutic range
- Target doses: sertraline 50-200 mg/day, paroxetine 20-50 mg/day
- Continue buspirone if it's providing some benefit without side effects, as there's no contraindication to combination therapy
Monitor for:
- Initial anxiety/agitation (common SSRI side effect in first 1-2 weeks) 7
- Serotonin syndrome risk is low with buspirone + SSRI, but watch for symptoms in first 24-48 hours after dose changes 7
- Treatment response typically requires 4-8 weeks 8
Alternative Considerations
If SSRIs fail or are not tolerated:
Second-line: Venlafaxine (SNRI) showed comparable efficacy (SMD = -0.29) and is recommended by VA/DoD guidelines 1, 2, 9
Avoid: The VA/DoD guideline provides a strong recommendation against benzodiazepines in PTSD, as they may worsen outcomes and increase PTSD rates (63% vs 23% placebo in one study) 10, 1
Common Pitfall
Do not add an antipsychotic as the next step. While quetiapine and risperidone have some evidence 2, 11, the VA/DoD guideline reserves these for augmentation after SSRI/SNRI trials have failed, not as initial add-on therapy 1. The evidence quality is substantially lower (very low-certainty) compared to SSRIs 3.
The dropout rate from SSRIs due to adverse events is only 9%, making tolerability concerns less significant than the substantial benefit in symptom reduction 3.